What's new — Retinoblastoma¶
Generated 2026-09-03 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 0 |
| last 2 months | 1 |
| last 3 months | 4 |
| last 6 months | 5 |
| last year | 18 |
| older than a year | 349 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
Trials — what has moved¶
11 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 0 |
| trial records updated in the last month | 1 |
| trial records updated in the last 2 months | 1 |
| trial records updated in the last 3 months | 1 |
| trial records updated in the last 6 months | 1 |
| trial records updated in the last year | 3 |
Recently updated registrations¶
| Updated | Trial | Phase | Status | N | Cited on |
|---|---|---|---|---|---|
| 2026-08-25 | A Study to Give Treatment Inside the Eye to Treat Retinoblastoma | PHASE2 | RECRUITING | 26 | clinical-trials-landscape |
| 2025-11-28 | Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategi | PHASE2, PHASE3 | RECRUITING | 225 | clinical-trials-landscape |
| 2025-09-19 | Studying Health Outcomes After Treatment in Patients With Retinoblastoma | NA | RECRUITING | 900 | clinical-trials-landscape |
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2019-06-26 | Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radi | PHASE3 | 60 | Event-free Survival (EFS) | 3 | 35 | 22 |
8 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| intra-arterial-chemotherapy | 2026-08-03 | 4 | 43 |
| enucleation-and-high-risk-pathology | 2026-07-03 | 4 | 41 |
| classification-and-staging | 2026-07-02 | 2 | 39 |
| global-access-and-outcome-disparity | 2026-07-01 | 3 | 43 |
| systemic-chemotherapy | 2026-07-01 | 3 | 41 |
| molecular-pathogenesis-and-cell-of-origin | 2026-05-01 | 3 | 41 |
| intravitreal-and-intracameral-chemotherapy | 2026-01-01 | 3 | 41 |
| clinical-presentation-and-diagnosis | 2025-12-01 | 2 | 45 |
| red-flags-and-safety-concerns | 2025-12-01 | 2 | 48 |
| vision-outcomes-and-patient-experience | 2025-12-01 | 2 | 43 |
| clinical-trials-landscape | 2025-10-02 | 1 | 38 |
| genetic-testing-and-counselling | 2025-09-02 | 0 | 41 |
| rb1-genetics-and-heritability | 2025-09-02 | 0 | 40 |
| overview | 2025-09-01 | 0 | 45 |
| second-cancers-and-survivorship | 2025-09-01 | 0 | 43 |
| extraocular-metastatic-and-trilateral-disease | 2025-07-04 | 0 | 43 |
| epidemiology-and-global-burden | 2025-07-02 | 0 | 40 |
| guidelines | 2025-05-01 | 0 | 44 |
| focal-therapy-and-brachytherapy | 2024-11-01 | 0 | 41 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.